Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:GHRS NASDAQ:INCR NASDAQ:LVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.40+0.1%$3.80$2.05▼$4.98$431.81M1.831.20 million shs648,483 shsGHRSGH Research$22.12$17.78$10.66▼$24.66$1.52B1.27213,905 shs350,785 shsINCRInterCure$0.88+0.1%$0.80$0.68▼$1.77$48.07M1.2424,562 shs2,471 shsLVTXLAVA Therapeutics$1.74$1.72$1.17▼$1.83$45.77M0.5187,834 shsN/AThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%+4.21%-13.72%-22.75%+40.58%GHRSGH Research0.00%+3.41%+9.23%+43.45%+98.03%INCRInterCure0.00%+7.20%-3.16%+3.41%-43.29%LVTXLAVA Therapeutics0.00%0.00%0.00%0.00%+35.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.40+0.1%$3.80$2.05▼$4.98$431.81M1.831.20 million shs648,483 shsGHRSGH Research$22.12$17.78$10.66▼$24.66$1.52B1.27213,905 shs350,785 shsINCRInterCure$0.88+0.1%$0.80$0.68▼$1.77$48.07M1.2424,562 shs2,471 shsLVTXLAVA Therapeutics$1.74$1.72$1.17▼$1.83$45.77M0.5187,834 shsN/AThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%+4.21%-13.72%-22.75%+40.58%GHRSGH Research0.00%+3.41%+9.23%+43.45%+98.03%INCRInterCure0.00%+7.20%-3.16%+3.41%-43.29%LVTXLAVA Therapeutics0.00%0.00%0.00%0.00%+35.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.50Moderate Buy$8.00135.64% UpsideGHRSGH Research 2.73Moderate Buy$40.3882.53% UpsideINCRInterCure 1.00SellN/AN/ALVTXLAVA Therapeutics 1.67Reduce$1.37-21.26% DownsideCurrent Analyst Ratings BreakdownLatest ADCT, GHRS, INCR, and LVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026GHRSGH Research HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.005/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/21/2026GHRSGH Research Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/23/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.003/10/2026GHRSGH Research GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$34.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M5.31N/AN/A($1.70) per share-2.00GHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/AINCRInterCure$270.20M0.18N/AN/A$2.11 per share0.42LVTXLAVA Therapeutics$4.99M9.17N/AN/A$1.06 per share1.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)GHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)INCRInterCure-$10.37M$0.0329.30N/AN/AN/AN/AN/AN/ALVTXLAVA Therapeutics-$25.11M-$0.86N/AN/AN/AN/A-107.63%-35.06%N/ALatest ADCT, GHRS, INCR, and LVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 million4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 million3/10/2026Q4 2025ADCTADC Therapeutics-$0.32-$0.04+$0.28-$0.04$22.29 million$23.06 million3/6/2026Q4 2025GHRSGH Research-$0.29-$0.23+$0.06-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.094.02GHRSGH ResearchN/A34.1334.13INCRInterCure0.201.480.97LVTXLAVA TherapeuticsN/A12.2712.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%GHRSGH Research56.90%INCRInterCure8.34%LVTXLAVA TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%GHRSGH Research41.60%INCRInterCure0.24%LVTXLAVA Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableGHRSGH Research1068.61 million40.07 millionOptionableINCRInterCure35054.68 million54.55 millionOptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableADCT, GHRS, INCR, and LVTX HeadlinesRecent News About These CompaniesBrokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69November 16, 2025 | defenseworld.netDLAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from NasdaqNovember 13, 2025 | globenewswire.comLAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 DeadlineNovember 10, 2025 | globenewswire.comInsider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells 690,239 Shares of StockOctober 21, 2025 | insidertrades.comShareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase AgreementOctober 20, 2025 | prnewswire.comLAVA Therapeutics N.V. Announces Amendment to Tender Offer and Extension of Extraordinary General Meeting DateOctober 17, 2025 | quiverquant.comQLAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells $73,436.44 in StockOctober 16, 2025 | insidertrades.comLAVA Therapeutics N.V. Stock (LVTX) Opinions on Insider Sales and Acquisition DelaysOctober 11, 2025 | quiverquant.comQInsider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells 28,954 Shares of StockOctober 11, 2025 | insidertrades.comLAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025September 30, 2025 | globenewswire.comLAVA Therapeutics N.V. (LVTX) - Yahoo FinanceAugust 20, 2025 | finance.yahoo.comLAVA Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of ShareholdersAugust 8, 2025 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)August 7, 2025 | prnewswire.comJefferies Downgrades LAVA Therapeutics N.V. (LVTX)August 5, 2025 | msn.comLAVA Therapeutics Shares Climb on Buyout Deal with XOMA RoyaltyAugust 4, 2025 | msn.comXOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA TherapeuticsAugust 4, 2025 | msn.comLVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to ShareholdersAugust 4, 2025 | businesswire.comLAVA Therapeutics Shareholders Approve Key Proposals in MeetingJune 13, 2025 | tipranks.comHere's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn SituationMay 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple’s Earnings Make $300 Look Like a Matter of When, Not IfBy Sam Quirke | May 1, 2026Meta Posted Its Best Sales Growth Since 2021—So Why Did Shares Fall?By Leo Miller | April 30, 2026Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%By Leo Miller | April 28, 20263 Stocks Poised to Grow on European Rearmament SpendingBy Nathan Reiff | April 26, 2026AI Dividend Increases: 3 Massive Winners Boosting PayoutsBy Leo Miller | May 11, 2026ADCT, GHRS, INCR, and LVTX Company DescriptionsADC Therapeutics NYSE:ADCT$3.40 +0.01 (+0.15%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$3.40 0.00 (0.00%) As of 05/22/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.GH Research NASDAQ:GHRS$22.12 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$22.42 +0.31 (+1.38%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.InterCure NASDAQ:INCR$0.88 +0.00 (+0.14%) Closing price 05/22/2026 03:40 PM EasternExtended Trading$0.84 -0.04 (-4.32%) As of 05/22/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.LAVA Therapeutics NASDAQ:LVTXLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
